MORGANTOWN, W.Va. – The WVU Cancer Institute has enrolled two of the first three patients in a national clinical trial for a novel breast cancer vaccine.
The trial, sponsored by the National Surgical Adjuvant Breast and Bowel Project (NSABP) Foundation, will examine the recommended biologic dose of a vaccine in combination with pembrolizumab, an immunotherapy drug that is used to fight certain cancers, in the treatment of patients with advanced triple-negative breast cancer.
“This vaccine works differently than traditional vaccines by helping to stimulate an immune response, which will enable the immunotherapy agent to uncloak and attack the cancer,” Sobha Kurian, M.D., WVU Medicine hematologist/oncologist and primary investigator of the study, said. “The immunotherapy by itself may not work against certain cancers because the cancer cells cloak themselves and often cannot be detected by the immune system, but this vaccine may help to overcome this problem.”
The WVU Cancer Institute joins 10 other cancer centers across the country in recruiting 29 patients for this study.
“The ability to participate in this study exemplifies the WVU Cancer Institute’s role as a leader in cancer research,” Dr. Kurian said. “The field of breast cancer research is constantly evolving, and we are honored to be at the forefront.”
Patients who receive the treatment will be closely monitored for up to 90 days to assess the efficacy of the drug and vaccine combination.
For more information on the WVU Cancer Institute, visit WVUMedicine.org/Cancer.
To date, the Norma Mae Huggins Cancer Research Endowment Fund has raised about $5 million to support clinical research trials for cancer patients in West Virginia. But, to the patients and physicians impacted by those funds, their value is priceless. To learn more, click here.
Officials from the WVU Health System and Uniontown Hospital gathered today (Sept. 25) to celebrate their affiliation agreement with the unveiling of new signage on the Hospital’s Fayette County campus.
WVCTSI receives $1.5 million NIH grant to lead 8-state participation in the National COVID Cohort Collaborative
Sally Hodder, MD, knew that West Virginia could be a leader in COVID-19 research, even in the early stages of the pandemic in the U.S. As early as March 2020, teams at the West Virginia Clinical and Translational Science Institute (WVCTSI) led by Dr. Hodder and WVU Medicine were hard at work to ensure that data from patients across the state could be analyzed to develop the most impactful research possible. The teams built a COVID-19 patient data registry that contained diagnoses, procedures, labs, medications, and outcomes for WVU Medicine patients tested for COVID-19. This registry became the foundation for this new funding award – a $1.5 million grant to lead a multi-state consortium within the National COVID Cohort Collaborative (N3C).
WVU Heart and Vascular Institute surgeon develops slipping rib syndrome repair procedure, changes lives
Chronic pain can be debilitating. Patients who live with pain often undergo thousands of dollars of often invasive testing in order to find answers and require long-term use of narcotics in order to function. Adam Hansen, M.D., a WVU Heart and Vascular Institute thoracic surgeon practicing at WVU Medicine United Hospital Center, has found a way to bring relief to patients whose chronic pain is caused by slipping rib syndrome.